Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment

BACKGROUND: Darolutamide is a second-generation androgen receptor inhibitor approved for the treatment of nonmetastatic castration-resistant prostate cancer at a dosage of 600 mg orally twice daily. OBJECTIVE: We aimed to fully characterize the pharmacokinetic profile of darolutamide, its diastereom...

Descripción completa

Detalles Bibliográficos
Autores principales: Zurth, Christian, Nykänen, Pirjo, Wilkinson, Gary, Taavitsainen, Päivi, Vuorela, Annamari, Huang, Funan, Reschke, Susanne, Koskinen, Mikko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975796/
https://www.ncbi.nlm.nih.gov/pubmed/34866168
http://dx.doi.org/10.1007/s40262-021-01078-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975796/
https://www.ncbi.nlm.nih.gov/pubmed/34866168
http://dx.doi.org/10.1007/s40262-021-01078-y

Ejemplares similares